logo

For the Inventor, By the Inventor

Dover, MA, United States of America

Amir Masoud Sadaghiani

This inventor holds 4 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Amir Masoud Sadaghiani. Retrieved from https://idiyas.com/inventor/amir-masoud-sadaghiani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 75.0

 

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal4 out of 3,977 
 
Novartis Ag
 patents

Years Active: 2022-2026

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 12760031 - Pyridine-3-carboxylate compounds as CA1.2 activators (2026-10-13),
2. 12365690 - Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Ca1.2 activators (2025-07-22),
3. 11919911 - Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators (2024-03-05),
4. 11453679 - Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators (2022-09-27),

Title: Innovations of Amir Masoud Sadaghiani

Introduction

Amir Masoud Sadaghiani is a notable inventor based in Dover, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating various mental health disorders. With a total of three patents to his name, Sadaghiani's work is recognized for its potential impact on healthcare.

Latest Patents

Sadaghiani's latest patents include innovative compounds such as Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate. These compounds are identified as Ca1.2 activators and are designed for the treatment of various conditions, including schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder, among others. The disclosures provide detailed formulations and potential applications for these compounds in therapeutic settings.

Career Highlights

Amir Masoud Sadaghiani is currently associated with Novartis AG, a leading global healthcare company. His role involves research and development of innovative pharmaceutical solutions. His expertise in medicinal chemistry and pharmacology has been instrumental in advancing the company's therapeutic offerings.

Collaborations

Sadaghiani has collaborated with notable colleagues such as James Neef and Tejaskumar Pankajbhai Pathak. These collaborations have fostered a productive environment for innovation and have contributed to the successful development of his patented compounds.

Conclusion

Amir Masoud Sadaghiani's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to improving mental health treatment options. His work continues to pave the way for advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…